ROCKWELL MEDICAL, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.63 USD | -1.21% |
|
+3.16% | -13.76% |
| 04-17 | Rockwell Medical Continues to Expand Its Distribution Capabilities in Western United States | CI |
| 04-04 | Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda | CI |
| Sales 2024 * | 88.97M 7.1B | Sales 2025 * | 101M 8.06B | Capitalization | 48.45M 3.87B |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -160M | Net income 2025 * | 1M 79.81M | EV / Sales 2024 * | 0.54 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.48 x |
| P/E ratio 2024 * |
-16.5
x | P/E ratio 2025 * |
27.5
x | Employees | 237 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Rockwell Medical, Inc.
More recommendations
More press releases
| 1 day | -1.21% | ||
| 1 week | +3.16% | ||
| Current month | +11.64% | ||
| 1 month | +3.16% | ||
| 3 months | +21.64% | ||
| 6 months | -11.41% | ||
| Current year | -13.76% |
1 week
1.58
1.72
1 month
1.421.72
Current year
1.161.94
1 year
1.166.24
3 years
0.8411.66
5 years
0.8458.85
10 years
0.84207.90
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Strobeck
CEO | Chief Executive Officer | 53 | 30/06/22 |
Jesse Neri
DFI | Director of Finance/CFO | 46 | 17/10/23 |
Marc Hoffman
CTO | Chief Tech/Sci/R&D Officer | 63 | 19/11/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Cooper
BRD | Director/Board Member | 65 | 06/09/17 |
Allen Nissenson
BRD | Director/Board Member | 77 | 10/06/20 |
Mark Strobeck
CEO | Chief Executive Officer | 53 | 30/06/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 1.63 | -1.21% | 32 123 |
| 09/05/24 | 1.65 | +3.12% | 52,051 |
| 08/05/24 | 1.6 | -2.44% | 37,133 |
| 07/05/24 | 1.64 | +1.86% | 124,378 |
| 06/05/24 | 1.61 | +1.90% | 51,763 |
Delayed Quote Nasdaq, May 10, 2024 at 08:34 pm
More quotes
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patientâs bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Sector
Pharmaceuticals
Calendar
14/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.65
USD
Average target price
7
USD
Spread / Average Target
+324.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.76% | 48.45M | |
| +30.69% | 695B | |
| +26.51% | 568B | |
| -4.46% | 361B | |
| +19.70% | 330B | |
| +3.73% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +8.27% | 168B |
- Stock Market
- Equities
- RMTI Stock
